CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

daunorubicin and cytarabine

Last Updated: December 17, 2020
Result type: Reports
Project Number: PC0237-000
Product Line: Reimbursement Review

Generic Name: daunorubicin and cytarabine

Brand Name: TBC

Manufacturer: Jazz Pharmaceuticals Canada Inc.

Therapeutic Area: Acute myeloid leukaemia

Indications: For the treatment of adults with newly diagnosed therapy-relatedacute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes(AML-MRC). For the treatment of relapsed or refractory AML in pediatric andyoung adult patients aged 1 to 21 years old.

Manufacturer Requested Reimbursement Criteria1: For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). For the treatment of relapsed or refractory AML in pediatric and young adult patients aged 1 to 21 years old.

Submission Type: Initial

Tumour Type: Leukemia

Project Status: Pending

Call for patient/clinician input open: December 17, 2020

Call for patient/clinician input closed: February 12, 2021

Anticipated Date: January 22, 2021

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback